United States - English - NLM (National Library of Medicine)

merus labs international inc. - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - gemifloxacin 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies. ) acute bacterial exacerbation of chronic bronchitis (abecb) caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . because fluoroquinolones, including factive, have been associated with serious adverse reactions (see warnings ) and for some patients abecb is self-limiting, reserve factive for treatment of abecb in patients who have no alternative treatment options. community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant s

United States - English - NLM (National Library of Medicine)

vansen pharma inc. - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - gemifloxacin 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies . ) acute bacterial exacerbation of chronic bronchitis caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant streptococcus pneumoniae , includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (mic ≥2 μg/ml), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. to reduce the development

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - gemifloxacin mesilate - film-coated tablet - 320 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

tabuk pharmaceutical manufacturing company, saudi arabia - gemifloxacin mesilate - film-coated tablet - 320 mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - gemifloxacin mesylate -

United States - English - NLM (National Library of Medicine)

oscient pharmaceuticals - gemifloxacin mesylate (unii: x4s9f8rl01) (gemifloxacin - unii:okr68y0e4t) - tablet - 320 mg - factive is indicated for the treatment of infections caused by susceptible strains of the designated microorganisms in the conditions listed below. (see dosage and administration and clinical studies . ) acute bacterial exacerbation of chronic bronchitis caused by streptococcus pneumoniae, haemophilus influenzae, haemophilus parainfluenzae, or moraxella catarrhalis . community-acquired pneumonia (of mild to moderate severity) caused by streptococcus pneumoniae (including multi-drug resistant strains [mdrsp])*, haemophilus influenzae, moraxella catarrhalis, mycoplasma pneumoniae, chlamydia pneumoniae, or klebsiella pneumoniae . *mdrsp: multi-drug resistant streptococcus pneumoniae , includes isolates previously known as prsp (penicillin-resistant streptococcus pneumoniae ), and are strains resistant to two or more of the following antibiotics: penicillin (mic ≥2 μg/ml), 2nd generation cephalosporins (e.g., cefuroxime), macrolides, tetracyclines and trimethoprim/sulfamethoxazole. to reduce the development

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - gemifloxacin mesilate sesquihydrate 426.39mg equivalent to 320 mg gemifloxacin pure free base;   - film coated tablet - 320 mg - active: gemifloxacin mesilate sesquihydrate 426.39mg equivalent to 320 mg gemifloxacin pure free base   excipient: crospovidone hypromellose macrogol 4000 macrogol 6000 magnesium stearate microcrystalline cellulose povidone titanium dioxide

Canada - English - Health Canada

oscient pharmaceuticals corporation - gemifloxacin (gemifloxacin mesylate) - tablet - 320mg - gemifloxacin (gemifloxacin mesylate) 320mg - quinolones

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

aspen-p -

Nigeria - English - NAFDAC (National Agency for Food and Drugs Administration and Control)

gemifloxacin 320mg